||**Trustees' Annual Report for the period**|**Trustees' Annual Report for the period**|**Trustees' Annual Report for the period**|**Trustees' Annual Report for the period**|**Trustees' Annual Report for the period**|**Trustees' Annual Report for the period**|**Trustees' Annual Report for the period**|**Trustees' Annual Report for the period**|**Trustees' Annual Report for the period**|**Trustees' Annual Report for the period**|**Trustees' Annual Report for the period**|**Trustees' Annual Report for the period**|**Trustees' Annual Report for the period**|||| |---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---| ||**From**|Period start date|||||**To**|Period end date||||||||| |||Day
6|Month
4|||Year
2021||Day
5|Month
4||||Year
2022|||| |||||||||||||||||| |Section A||Reference and administration details||||||||||||||| |||||||||||||||||| ||**Charity name**|||
Amyloid Action||||||||||||| |||||||||||||||||| |**Other names charity is known by**|||||Non|||||||||||| |||||||||||||||||| |**Registered charity number (if any)**|||||1171957|||||||||||| |||||||||||||||||| |**Charity's principal address**|||||
94 MAINS LANE|||||||||||| ||||||POULTON-LE-FYLDE|||||||||||| ||||||LANCS|||||||||||| ||||||**Postcode**||||||FY6 7LD|||||| |||||||||||||||||| |**Names of the charity trustees who manage the charity**
**Trustee name**
**Office (if any)**
**Dates acted if not for**
**whole year**
1
Richard Preston
Chair
2
Kathryn May
Preston
3
Charles James
Purvis
4
Professor Adrian
Bloor
5
Professor Julian
Gillmore
6
7
8
9
10||||||||||||**Name of person (or body) entitled**
**to appoint trustee (if any)**||||| |||||||||||||||||| |||||||||||||||||| |||||||||||||||||| |||||||||||||||||| |||||||||||||||||| |||||||||||||||||| |||||||||||||||||| |||||||||||||||||| |||||||||||||||||| |||||||||||||||||| March **2012** **TAR** 1 11 12 13 14 15 16 17 18 19 20 **Names of the trustees for the charity, if any, (for example, any custodian trustees) Name Dates acted if not for whole year** ## **Names and addresses of advisers (Optional information)** **Type of adviser Name Address Name of chief executive or names of senior staff members (Optional information)** ## **Section B Structure, governance and management** ## **Description of the charity’s trusts** > Type of governing document CIO Foundation Constitution (eg. trust deed, constitution) > How the charity is constituted Constitution of a CIO whose only voting members are (eg. trust, association, company) its charity trustees > Trustee selection methods Elected by other trustees (eg. appointed by, elected by) ## **Additional governance issues (Optional information)** March **2012** **TAR** 2 You **may choose** to include additional information, where relevant, about: All trustees give of their time freely and no trustee remuneration was paid in the year. No trustee expenses were claimed in the year. - policies and procedures adopted for the induction and training of trustees; - the charity’s organisational structure and any wider network with which the charity works; - relationship with any related parties; - trustees’ consideration of major risks and the system and procedures to manage them. ## **Section C Objectives and activities** **Summary of the objects of the charity set out in its governing document** To assist in the treatment and care of persons suffering from amyloidosis in England and Wales by the provision of equipment, facilities, services, financial assistance, support, education and practical advice. To advance the education of the general public and medical professionals in all areas relating to amyloidosis. March **2012** **TAR** 3 |**Summary of the main activities**
**undertaken for the public**
**benefit in relation to these**
**objects (include within this**
**section the statutory**
**declaration that trustees have**
**had regard to the guidance**
**issued by the Charity**
**Commission on public benefit)**|Amyloid Action has established its grant making
policy to achieve its objects for raising funds for
equipment and research at the National Amyloidosis
Centre and the Christie Hospital and for the public
benefit of improving the lives of amyloidosis sufferers
by providing funds and equipment to sufferers and
also to raise awareness/education about this rare
disease of Amyloidosis amongst the general public.
We have continued to deliver virtual presentations
and discussions throughout our professional network
- these include The Institution of Engineering and
Technology, The association for Project Management,
universities and medical organisations. This has both
raised funds and helped to raise awareness of this
little known disease.
In carrying out all of the above, the trustees confirm
that they have referred to the guidance contained in
the Charity Commission’s general guidance on public
benefit when reviewing our aims and objectives and
in planning future activities and setting the grant
making policy for the year.| |---|---| **Additional details of objectives and activities (Optional information)** You **may choose** to include further statements, where relevant, about: - policy on grantmaking; - policy programme related investment; - contribution made by volunteers. March **2012** **TAR** 4 Section D Achievements and performance **Summary of the main achievements of the charity during the year** Our activities have been mainly virtual discussions with a limited return to face to face. Whereas, we have probably reached a wider audience with regards to spreading awareness of amyloidosis, carried out through our activities with professional and trade bodies and educational establishments, our fundraising has been restricted. March **2012** **TAR** 5 ## **Section E Financial review** > **Brief statement of the** The charity has minimal overheads and accordingly does not need > **charity’s policy on reserves** large reserves. A minimum balance of around £200 is envisaged. ## **Details of any funds materially in deficit** ## **Further financial review details (Optional information)** You **may choose** to include additional information, where relevant about: - the charity’s principal sources of funds (including any fundraising); - how expenditure has supported the key objectives of the charity; - investment policy and objectives including any ethical investment policy adopted. ## **Section F Other optional information** ## **Section G Declaration** **The trustees declare that they have approved the trustees’ report above.** **Signed on behalf of the charity’s trustees** **Signature(s)** March **2012** **TAR** 6 > **Full name(s)** Richard Preston > **Position (eg Secretary, Chair, etc)** Chair **Dat** 31/1/2023 March **2012** **TAR** 7 ||**Charity Name**|**Charity Name**|**Charity Name**|**Charity Name**|**Charity Name**|**No(if any)**|**No(if any)**||**CC16a**| |---|---|---|---|---|---|---|---|---|---| ||**AMYLOID ACTION**|||||**1171957**|||| ||**Receipts andpayments accounts**||||||||| ||**For the period**
**from**||Period start date||**To**||Period end date||| ||||06/04/2021||||05/04/2022||| ||||||||||| |**Section A Receipts and payments**|||||||||| ||**Unrestricted**
**funds**||**Restricted funds**||**Endowment**
**funds**||**Total funds**||**Last year**| ||**to the nearest £**||**to the nearest £**||**to the nearest £**||**to the nearest £**||**to the nearest £**| |**A1 Receipts**|||||||||| |Voluntary Donations|**2,119**||**-**||**-**||**2,119**||**-**| |Interest (CAF Gold Account)|**1**||**-**||**-**||**1**||**-**| ||**- 0**||||**-**||**-**||**-**| ||**- 0**||**-**||**-**||**-**||**-**| |**_Sub total_**_(Gross income for AR)_|
**2,120**||**-**||**-**||**2,120**||**-**| ||||||||||| |**A2 Asset and investment sales,**
**(see table).**|||||||||| ||**- 0**||**- 0**||**- 0**||**-**||| ||**- 0**||**- 0**||**- 0**||**-**||**- 0**| |**_Sub total_**|
**- 0**||**- 0**||**- 0**||**-**||**- 0**| ||||||||||| |**_Total receipts_ **|
**2,120**||**- 0**||**- 0**||**2,120**||**- 0**| ||||||||||| |**A3 Payments**|||||||||| |CAF Bank Monthly Charges|**96**||**-**||**-**||**96**||**-**| |Chamber of Commerce|||**-**||**-**||**-**||**-**| ||**- 0**||**-**||**-**||**-**||**-**| |**_Sub total_ **|
**96**||**-**||**-**||**96**||**-**| ||||||||||| |**A4 Asset and investment**
**purchases, (see table)**|||||||||| ||**- 0**||**- 0**||**- 0**||**-**||| ||**- 0**||**- 0**||**- 0**||**-**||| |**_Sub total_ **|
**- 0**||**- 0**||**- 0**||**-**||**- 0**| ||||||||||| |**_Totalpayments_ **|
**96**||**- 0**||**- 0**||**96**||**- 0**| ||||||||||| |**_Net of receipts/(payments)_ **|
**2,024**||**-**||**-**||**2,024**||**-**| |**A5 Transfers between funds**|**- 0**||**-**||**-**||**-**||**-**| |**A6 Cash funds lastyear end**|**- 0**||**-**||**-**||**-**||**-**| |**_Cash funds thisyear end_ **|
**2,024**||**-**||**-**||**2,024**||**-**| ||||||||||| ||||||||||| |**Section B Statement of assets and liabilities at the end of the period**|||||||||| |**Categories**|**Details**||||**Unrestricted**
**funds**||**Restricted funds**||**Endowment**
**funds**| ||||||**to nearest £**||**to nearest £**||**to nearest £**| |**B1 Cash funds**|CAF Bank Cash Account||||**2,919**||**-**||**-**| ||CAF Bank Gold Account||||**8,018**||**-**||**-**| ||||||**-**||**-**||**-**| ||**_Total cash funds_**||||**10,937**||**-**||**-**| ||(agree balances with receipts and payments
account(s))||||Agreement Error||||OK| ||||||**Unrestricted**
**funds**||**Restricted funds**||**Endowment**
**funds**| ||**Details**||||**to nearest £**||**to nearest £**||**to nearest £**| |**B2 Other monetary assets**|||||**-**||**-**||**-**| ||||||**-**||**-**||**-**| ||||||**-**||**-**||**-**| ||||||**-**||**-**||**-**| ||||||**-**||**-**||**-**| ||||||**-**||**-**||**-**| ||||||||||| CCXX R1 accounts (SS) 01/02/2021 1 ||**Details**|**Details**|**Details**||**Fund to which asset**
**belongs**||**Cost (optional)**||**Current value**
**(optional)**| |---|---|---|---|---|---|---|---|---|---| |**B3 Investment assets**|||||||**-**||**-**| ||||||||**-**||**-**| ||||||||**-**||**-**| ||||||||**-**||**-**| ||||||||**-**||**-**| ||||||||||| ||**Details**||||**Fund to which asset**
**belongs**||**Cost (optional)**||**Current value**
**(optional)**| |**B4 Assets retained for the**
**charity’s own use**|||||||**-**||**-**| ||||||||**-**||**-**| ||||||||**-**||**-**| ||||||||**-**||**-**| ||||||||**-**||**-**| ||||||||**-**||**-**| ||||||||**-**||**-**| ||||||||**-**||**-**| ||||||||**-**||**-**| ||||||||||| ||**Details**||||**Fund to which**
**liability relates**||**Amount due**
**(optional)**||**When due**
**(optional)**| |**B5 Liabilities**|||||||**-**||| ||||||||**-**||| ||||||||**-**||| ||||||||**-**||| ||||||||**-**||| ||||||||||| |Signed by one or two trustees on behalf
of all the trustees|Signature||||Print Name||||Date of approval| ||||||RICHARD PRESTON||||29/1/23| CCXX R2 accounts (SS) 01/02/2021 2